The Orthopaedics division of Contura aims to provide patients relief from the symptoms of
osteoarthritis, an area where current treatment options are limited and where it is
predicted that 10% of people over the age of 55 will suffer symptoms.

Arthrosamid fulfils the unmet clinical need for a long-acting, safe and minimally invasive
treatment that may prevent or postpone knee surgery.

Product image

Arthrosamid is a non-biodegradable hydrogel used for the treatment of symptomatic
osteoarthritis of the knee.

Once injected into the intra-articular cavity of the knee joint, Arthrosamid integrates
into the synovial tissue to provide long-lasting cushioning of the inner joint,
reducing pain and decreasing joint stiffness. Following the completion of a three-month
prospective open label study, which demonstrated significant pain reduction in patients
with osteoarthritis of the knee, Arthrosamid received European approval in 2020.

Latest news

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.